| Sign In to gain access to subscriptions and/or personal tools. |
Chlorpromazine Inhibition of Muscarinic-Cholinergic Responses in the Rat Parotid GlandClinical Investigations and Patient Care Branch, National Institute of Dental Research, National Institutes of Health, Building 10, Room 1A-06, Bethesda, Maryland 20892
Clinical Investigations and Patient Care Branch, National Institute of Dental Research, National Institutes of Health, Building 10, Room 1A-06, Bethesda, Maryland 20892
Clinical Investigations and Patient Care Branch, National Institute of Dental Research, National Institutes of Health, Building 10, Room 1A-06, Bethesda, Maryland 20892 The ability of chlorpromazine (CPZ) to inhibit muscarinic-cholinergic secretory events was studied in vitro in rat parotid acinar cells. CPZ inhibited carbachol-induced amylase release in a dose-dependent fashion but had no effect on that elicited by isoproterenol. The inhibition of parotid protein synthesis induced by carbachol, but not that induced by A23187, was blocked by CPZ. CPZ exhibited a dose-dependent inhibition of [3H]quinuclidinyl benzilate (QNB) binding to muscarinic receptors, and altered the KD of the receptor for the ligand. These results are consistent with an ability of CPZ to inhibit muscarinic-cholinergic-induced salivary secretion by complex interference with receptor binding. In addition, CPZ may block parotid-muscarinic responses by impeding a post-receptor signaling step which is proximal to Ca2+ mobilization.
Journal of Dental Research, Vol. 65, No. 3,
382-386 (1986) This article has been cited by other articles:
|
|
|||||||||||||||||||||||||||


